|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davis A, Tinker AV and Friedlander M:
‘Platinum resistant’ ovarian cancer: What is it, who to treat and
how to measure benefit? Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J and Sen S: MicroRNA functional
network in pancreatic cancer: From biology to biomarkers of
disease. J Biosci. 36:481–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan SY and Loscalzo J: MicroRNA-210: A
unique and pleiotropic hypoxamir. Cell Cycle. 9:1072–1083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vera O, Jimenez J, Pernia O,
Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R,
Lopez-Magallon S, Esteban Rodriguez I, et al: DNA methylation of
miR-7 is a mechanism involved in platinum response through MAFG
overexpression in cancer cells. Theranostics. 7:4118–4134. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Du J, Li X, Su J, Huang Y, Ding N,
Zhang M and Jiang S: miR-509-3p promotes cisplatin-induced
apoptosis in ovarian cancer cells through the regulation of
anti-apoptotic genes. Pharmacogenomics. 18:1671–1682. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Zhang JY, Lu LJ, Wang CH and Wang
LH: MiR-630 promotes epithelial ovarian cancer proliferation and
invasion via targeting KLF6. Eur Rev Med Pharmacol Sci.
21:4542–4547. 2017.PubMed/NCBI
|
|
11
|
Han X, Zhang Y, Wang D, Fu X, Li M and
Wang A: Upregulation of microRNA-18b induces phosphatase and tensin
homolog to accelerate the migration and invasion abilities of
ovarian cancer. Oncol Lett. 14:5631–5637. 2017.PubMed/NCBI
|
|
12
|
Giannakakis A, Sandaltzopoulos R, Greshock
J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros
D, Weber BL, et al: miR-210 links hypoxia with cell cycle
regulation and is deleted in human epithelial ovarian cancer.
Cancer Biol Ther. 7:255–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L,
Yu Y, Liu S, Li S, Li Z and Sun L: Tolerance to endoplasmic
reticulum stress mediates cisplatin resistance in human ovarian
cancer cells by maintaining endoplasmic reticulum and mitochondrial
homeostasis. Oncol Rep. 34:3051–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang X, Ding L, Bennewith KL, Tong RT,
Welford SM, Ang KK, Story M, Le QT and Giaccia AJ:
Hypoxia-inducible mir-210 regulates normoxic gene expression
involved in tumor initiation. Mol Cell. 35:856–867. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malzkorn B, Wolter M, Liesenberg F,
Grzendowski M, Stühler K, Meyer HE and Reifenberger G:
Identification and functional characterization of microRNAs
involved in the malignant progression of gliomas. Brain Pathol.
20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Puissegur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsuchiya S, Fujiwara T, Sato F, Shimada Y,
Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast
growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang X, Shi L, Yi C, Yang Y, Chang L and
Song D: MiR-210-3p inhibits the tumor growth and metastasis of
bladder cancer via targeting fibroblast growth factor receptor-like
1. Am J Cancer Res. 7:1738–1753. 2017.PubMed/NCBI
|
|
21
|
Nakashima S, Jinnin M, Kanemaru H,
Kajihara I, Igata T, Okamoto S, Tazaki Y, Harada M, Masuguchi S,
Fukushima S, et al: The role of miR-210, E2F3 and ephrin A3 in
angiosarcoma cell proliferation. Eur J Dermatol. 27:464–471.
2017.PubMed/NCBI
|
|
22
|
Yoshino H, Yonemori M, Miyamoto K,
Tatarano S, Kofuji S, Nohata N, Nakagawa M and Enokida H:
microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis
through revival of TWIST1 in renal cell carcinoma. Oncotarget.
8:20881–20894. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Huang K, You Y, Fu X, Hu L, Song L
and Meng Y: Hypoxia-induced miR-210 in epithelial ovarian cancer
enhances cancer cell viability via promoting proliferation and
inhibiting apoptosis. Int J Oncol. 44:2111–2120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vandamme B, Lissens W, Amfo K, De Sutter
P, Bourgain C, Vamos E and De Grève J: Deletion of chromosome
11p13-11p15.5 sequences in invasive human ovarian cancer is a
subclonal progression factor. Cancer Res. 52:6646–6652.
1992.PubMed/NCBI
|
|
25
|
Viel A, Giannini F, Tumiotto L,
Sopracordevole F, Visentin MC and Boiocchi M: Chromosomal
localisation of two putative 11p oncosuppressor genes involved in
human ovarian tumours. Br J Cancer. 66:1030–1036. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vaksman O, Stavnes HT, Kaern J, Trope CG,
Davidson B and Reich R: miRNA profiling along tumour progression in
ovarian carcinoma. J Cell Mol Med. 15:1593–1602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reimer D, Hubalek M, Riedle S, Skvortsov
S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee
K, et al: E2F3a is critically involved in epidermal growth factor
receptor-directed proliferation in ovarian cancer. Cancer Res.
70:4613–4623. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reimer D, Hubalek M, Kiefel H, Riedle S,
Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H,
Müller-Holzner E, et al: Regulation of transcription factor E2F3a
and its clinical relevance in ovarian cancer. Oncogene.
30:4038–4049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song L, Duan P, Gan Y, Li P, Zhao C, Xu J,
Zhang Z and Zhou Q: MicroRNA-340-5p modulates cisplatin resistance
by targeting LPAATbeta in osteosarcoma. Braz J Med Biol Res.
50:e63592017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yi DY, Su Q, Zhang FC, Fu P, Zhang Q, Cen
YC, Zhao HY and Xiang W: Effect of microRNA-128 on cisplatin
resistance of glioma SHG-44 cells by targeting JAG1. J Cell
Biochem. 119:3162–3173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB
and Shao GG: Prognostic significance of serum microRNA-210 levels
in nonsmall-cell lung cancer. J Int Med Res. 41:1437–1444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao HM, Wei W, Sun YH, Gao JH, Wang Q and
Zheng JH: MicroRNA-9 promotes tumorigenesis and mediates
sensitivity to cisplatin in primary epithelial ovarian cancer
cells. Tumour Biol. 36:6867–6873. 2015. View Article : Google Scholar : PubMed/NCBI
|
